Jiangsu Hengrui Medicine Co., Ltd.

About Jiangsu Hengrui Medicine Co., Ltd.

     Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. In 1997, it was restructured into a joint-stock company. In 2000 Hengrui was listed on Shanghai Stock Exchange under stock code 600276. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 55 billion USD, and is home to more than 21,900 employees worldwide. Hengrui stands out as a front-runner in cancer drugs, contrast agents, and surgical medicines. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA. We have 11 R&D centers where over 3,000 research staff work on hundreds of therapeutic candidates, many of which may become first-in-class or best-in-class products. Hengrui conducts most of its clinical trials using in-house capabilities that cover medical, trial operations, data management, statistics, and regulatory. This allows us to better control speed and quality. Embracing the spirit of “Honesty and Trustworthiness, Quality First” as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets. Pursuing the concept of “Excelling in Science, Enhancing Life”, Hengrui sees its future as a Chinese multi-national pharmaceutical corporation, and continuously strives for innovation, progress, and achievement of new breakthrough in the healthcare industry. Contact: Mr Dong Wei
Email: [email protected], [email protected]

Certifications

Jiangsu Hengrui Medicine Co., Ltd.

  • CN
  • 2015
    On CPhI since
  • 2
    Certificates
  • 5000+
    Employees
Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy
9-11 November 2021

Products from Jiangsu Hengrui Medicine Co., Ltd.

  • Sevoflurane Inhalation Anesthetic

    Product Sevoflurane Inhalation Anesthetic

    Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as aninhalational anaesthetic for induction and maintenance of general anesthesia.

    Strength: 250ml.


    Sevoflurane Inhalation Anesthetic was approved by NMPA and launched in Chinese market in 2007 which is used in the induction and maintenance of the general anesthetic of pediatric in-patient and out-patient surgery. In November 2015, it was approved by US FDA and launched in US market and in 2016 got the approval to get launched in EU (MA in Germany, Netherlands and Netherlands).
  • Desflurane for inhalation

    Product Desflurane for inhalation

    Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia.

    Strength: 240ml

    It is approved by NMPA.
    It is approved by US-FDA and EU.

  • Dexmedetomidine HCl Injection

    Product Dexmedetomidine HCl Injection

    Dexmedetomide HCl is an anxiolytic, sedative, andanalgesic medication.

    Strength: 200mcg/2ml (100mcg/ml); Single-dose Vial
    This product has been approved by CFDA and US-FDA.

    Strength: 80mcg/20ml; 200mcg/50ml; 400mcg/100ml
    This product has been approved by NMPA and US -FDA.
  • Atracurium Besylate

    Product Atracurium Besylate

    Atracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent.

    It is approved by NMPA.
  • Butorphanol Tartrate

    Product Butorphanol Tartrate

    Butorphanol Tartate is a morphinan-type synthetic opioid analgesic.

    It is approved by NMPA.
  • Salmeterol xinafoate + Fluticasone propionate

    Product Salmeterol xinafoate + Fluticasone propionate

    It is indicated for asthma.It is still in R&D stage.
  • Sugammadex Sodium

    Product Sugammadex Sodium

    Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults.It is still in R&D stage and estimated to be approved by 2020.
  • Paricalcitol

    Product Paricalcitol

    Paricalcitol is a synthetic vitamin D analogue. Paricalcitol has been used to reduce parathyroid hormone levels. It is still in R&D stage, and estimated to be approved by 2020.
  • Ondansetron

    Product Ondansetron

    A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.It is still in R&D stage and estimated to be approved by 2020.
  • Febuxostat

    Product Febuxostat

    Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management.It is still in R&D stage and estimated to be approved by 2020.
  • Capecitabine

    Product Capecitabine

    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body.

    It is approved by NMPA.
  • Caspofungin Acetate

    Product Caspofungin Acetate

    Caspofungin Acetate is a lipopeptide antifungal drug. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration. It is administered intravenously.
    It is approved by NMPA.
    For this API product, US-DMF and EDMF of this API is available.  It has been exported to multiple countries in Asia, North African and South American.

Jiangsu Hengrui Medicine Co., Ltd. Resources